STAT+: Roche gets a lung cancer win with its KRAS drug divarasib

You’re reading our ESMO in 30 Seconds newsletter. Sign up here to get updates from future major European cancer conferences in your inbox.

We’ve made it. Here’s our last newsletter from this year’s European Society for Medical Oncology meeting. But before we bust out of this convention center for the final time, a reminder that we’ll be recapping ESMO on Thursday at 10 a.m. Eastern. Register for the virtual event here, and thanks very much for reading.  

Roche gets a lung cancer win

One of the more impressive data sets at this year’s ESMO came from a Roche study of its drug divarasib, which inhibits G12C KRAS mutations, in second-line advanced non-small cell lung cancer, where it outpaced older KRAS inhibitors from Amgen and Bristol Myers Squibb.

Continue to STAT+ to read the full story…